Compare ARGX & OXY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARGX | OXY |
|---|---|---|
| Founded | 2008 | 1920 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.9B | 39.3B |
| IPO Year | 2017 | N/A |
| Metric | ARGX | OXY |
|---|---|---|
| Price | $747.68 | $62.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 22 |
| Target Price | ★ $1,008.56 | $56.50 |
| AVG Volume (30 Days) | 304.0K | ★ 18.0M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.23 | $2.67 |
| Revenue Next Year | $22.38 | $4.50 |
| P/E Ratio | $33.69 | ★ $29.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $510.06 | $34.79 |
| 52 Week High | $934.62 | $67.45 |
| Indicator | ARGX | OXY |
|---|---|---|
| Relative Strength Index (RSI) | 56.09 | 64.41 |
| Support Level | $698.92 | $40.90 |
| Resistance Level | $779.00 | N/A |
| Average True Range (ATR) | 17.10 | 2.22 |
| MACD | 11.38 | -0.19 |
| Stochastic Oscillator | 87.92 | 54.17 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1.327 million barrels of oil equivalent per day in 2024 at a ratio of roughly 52% oil and natural gas liquids and 48% natural gas.